Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LepVax in leprosy endemic areas
NCT03947437Phase 2Unknown
- Sponsor
- Immunobiological Technology Institute
- Start
- Feb 2024
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of LepVax in leprosy (HD), sponsored by Immunobiological Technology Institute. Status: unknown.
02
Drugs
LepVax
03
Conditions
leprosy (HD)
Beyond the preview
Go deeper on NCT03947437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03947437.